Epstein-Barr virus encephalitis in solid organ transplantation

New Microbiol. 2017 Jul;40(3):212-217. Epub 2017 May 17.

Abstract

Epstein-Barr virus (EBV) is typically associated with post transplant lymphoproliferative disease (PTLD) after solid organ and stem cell transplantation. However, it is rarely associated with neurological complications. We report a case of severe encephalitis complicating primary EBV infection six months post renal transplantation, and review the literature on EBV encephalitis in solid organ transplantation in adults. A 55-year-old male presented 6 months post cadaveric renal transplant with headache, fever and confusion. Neuroimaging was unremarkable, but an electroencephalogram was consistent with diffuse encephalopathy. EBV DNA was detected in both cerebrospinal fluid (13,177 copies/ml), and plasma (14,166 copies/ml). Management included reduction of immunosuppression, intravenous ganciclovir and intravenous immunoglobulin, and resulted in a reduction in EBV viral load in both plasma and cerebrospinal fluid. The patient made a full recovery with no long-term neurological deficits and preservation of the graft. This case highlights the importance of knowing donor and recipient EBV serostatus at time of transplant, and closely monitoring EBV DNA when there is a mismatch. Ganciclovir or valganciclovir prophylaxis has also been shown to reduce the incidence of primary EBV infection in renal transplantation in these recipients. Treatment options for EBV infection post-transplant include reduction of immunosuppression, antiviral therapy, IVIg, and monoclonal antibody therapy directed toward infected B lymphocytes.

Keywords: Encephalitis; Epstein-Barr virus; Immunosuppression; Transplant.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Antiviral Agents / therapeutic use
  • DNA, Viral / cerebrospinal fluid
  • Encephalitis, Viral / drug therapy
  • Encephalitis, Viral / etiology*
  • Epstein-Barr Virus Infections / drug therapy
  • Epstein-Barr Virus Infections / etiology*
  • Ganciclovir / therapeutic use
  • Herpesvirus 4, Human / genetics
  • Herpesvirus 4, Human / isolation & purification
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Immunologic Factors / therapeutic use
  • Kidney Transplantation*
  • Male
  • Middle Aged
  • Postoperative Complications / drug therapy
  • Postoperative Complications / virology*
  • Viral Load

Substances

  • Antiviral Agents
  • DNA, Viral
  • Immunoglobulins, Intravenous
  • Immunologic Factors
  • Ganciclovir